Superiority of Buprenorphine over Suboxone in Preventing Addiction Relapse in Opioid Addicts under Maintenance Therapy: A Double-Blind Clinical Trial
Language: EnglishView: 108
This Paper With 6 Page And PDF Format Ready To Download
با استفاده از پرداخت اینترنتی بسیار سریع و ساده می توانید اصل این Paper را که دارای 6 صفحه است به صورت فایل PDF در اختیار داشته باشید.
Background: In maintenance therapy for opioid addiction, to reduce the risk of buprenorphine (BUP) abuse, the combination of BUP and naloxone (NX) has been developed and is commercially available as suboxone (BUP/NX). This study was designed to compare addiction relapse frequency in patients receiving BUP and BUP/NX as maintenance therapy. Methods: In this double-blind clinical trial with cross over design, 100 opioid abusers were randomly assigned to two treatment groups to receive either BUP or BUP/NX. After three months, without a time-out period, subjects undertook treatment with the other drug. The subjects were screened weekly for urinary morphine. Results: In each of the study arms, when the patients were given BUP/NX, the number of relapses was significantly higher compared to when they received BUP (0.13±0.24 vs. 0.04±0.09, P = 0.001). If participants’ age was taken into account, the number of relapses was significantly higher when BUP/NX was given in age groups of 31 to 40 years and over 50 years (P < 0.05). The length of addiction had also a significant impact on the number of relapses, i.e., patients with over 10-year history of addiction had higher number of relapses if they were given BUP/NX compared with BUP (P < 0.05). Conclusion:BUP seems to be more effective than BUP/NX in preventing addiction relapse in opioid abusers under maintenance treatment.
Buprenorphine, Naloxone Drug Combination, Opioid-Related Disorders, Recurrence
Paper COI CodeThis Paper COI Code is JR_PJMT-7-1_001. Also You can use the following address to link to this article. This link is permanent and is used as an article registration confirmation in the Civilica reference:
How to Cite to This Paper:
If you want to refer to this Paper in your research work, you can simply use the following phrase in the resources section:
Shojaei Ghalehney, Zahra and Ilbeigi, Shahram and Arshadi, Hamid Reza and Afshari, Reza,1397,Superiority of Buprenorphine over Suboxone in Preventing Addiction Relapse in Opioid Addicts under Maintenance Therapy: A Double-Blind Clinical Trial,,,,,https://civilica.com/doc/890597
مراجع و منابع این Paper:لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
United Nations Office on Drugs and Crime (UNODC). World Drug ...Forouzanfar MH, Sepanlou SG, Shahraz S, Dicker D, Naghavi P, ...Degenhardt L, Hall W. Extent of illicit drug use and ...GhaneT, Behmanesh Y, Alizadeh Ghamsari A, Amini M, Siavashian F, ...Karrari P, Mehrpour O, Afshari R, Keyler D. Pattern of ...Sharifi H, Kharaghani R, Sigari S, Emami H, Sadr M, ...Esmaeili HR, Ziaddinni H, Nikravesh MR, Baneshi MR, Nakhaee N. ...Center for Substance Abuse Treatment (CSAT). Treatment Improvement Protocol (TIP) ...Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability ...Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine ...Johnson RE, Strain EC, Amass L. Buprenorphine: how to use ...Robinson SE. Buprenorphine-containing treatments: place in the management of opioid ...Bart G. Maintenance medication for opiate addiction: the foundation of ...Johnson RE, Strain EC, Amass L. Buprenorphine: how to use ...Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and ...Afshari R. Non-medical Use of Medications in Middle and Low ...Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use ...Farzaneh E, Amani F, Etemad FA. Clinico-Epidemiological Study on Patients ...Khosrojerdi H, Monzavi SM, Afshari R. Blood products used in ...Ghaemi N, Alikhani S, Bagheri S, Sezavar M. A Cross ...Koushesh HR, Afshari R, Afshari R. A new illicit opioid ...Afshari R, Tabeshpour J. First scientific report of a new ...Gheshlaghi F, Izadi-Mood N, Mardani A, Piri-Ardekani MR. Dose-Dependent Effects ...Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. ...Magnelli F, Biondi L, Calabria R, Fiore A, Peluso E, ...Stimolo C, Favero VD, Zecchinato G, Buson R, Cusin D, ...Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, ...Amato P. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in ...Mammen K, Bell J. The clinical efficacy and abuse potential ...Bell J, Byron G, Gibson A, Morris A. A pilot ...